


PHARMACEUTICAL 2017




Viracta Therapeutics Inc. Rank 157 of 292





PHARMACEUTICAL 2017





The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 65%, being 62% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	43,231
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,939
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-11
Other Expenses	1,721
Other Liabilities	0
Other Net Income	158
Other Revenues	2,536
Property and Equipment	3.0
Research and Development	22,881
Selling, General and Administrative Expense	16,115

Output Variable	Value in 1000 USD
Assets	43,234
Liabilities	10,939
Expenses	40,717
Revenues	2,536
Stockholders Equity	32,295
Net Income	-38,023
Comprehensive Net Income	-38,028
Economic Capital Ratio	65%

